A Comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes

Medical Decision Making

Volumn 34, Issue 7, 2014, Pages 919-930

  Hernández Alava, Mónica ^a   Wailoo, Allan ^a   Wolfe, Fred ^b   Michaud, Kaleb ^b,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

EQ 5D; mapping; rheumatoid arthritis; statistical methods

Indexed keywords

ANTIRHEUMATIC AGENT;

ARTHRITIS, RHEUMATOID; COST BENEFIT ANALYSIS; DISABILITY; ECONOMICS; HUMAN; OUTCOME ASSESSMENT; PROCEDURES; STATISTICAL MODEL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; HUMANS; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84907674332     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X13500720     Document Type: Article

References (22)

1. Mortimer D, Segal L, Sturm J. Can we derive an "exchange rate" between descriptive and preference-based outcome measures for stroke? Results from the transfer to utility (TTU) technique. Health Qual Life Outcomes. 2009 ; 7: 33
2. KearnsBAraRWailooAJ. A review of the use of statistical regression models to inform cost effectiveness analyses within the NICE technology appraisals programme. Report by the NICE Decision Support Unit. August2012. Available at: URL http://www.nicedsu.org.uk/FINAL%20DSU%20Regressions%20report-09.10.12.pdf
3. Brazier J, Yang Y, Tsuchiya A, Rowen D. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010 ; 11: 215-25.
4. Hernández Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D health state utility values. Value Health. 2012 ; 15: 550-61
5. Hernández AlavaMWailooAWolfeFMichaudK. The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis: further validation and development of the limited dependent variable, mixture model approach, HEDS Discussion Paper 12/10. Available from: URL: http://www.shef.ac.uk/polopoly-fs/1.199216!/file/hedsdp1210.pdf
6. Gray A, Rivero-Arias O, Clarke P. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making. 2006 ; 26 (1). 18-29
7. Tobin J. Estimation of relationships for limited dependent variables. Econometrica. 1958 ; 26: 24-36
8. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ5D health states: development and testing of the D1 valuation model. Med Care. 2005 ; 43: 203-9
9. Dakin H, Gray A, Murray D. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score. Qual Life Res. 2013 ; 22 (3). 683-94
10. Rivero Arias O, Ouellet M, Gray A, et al. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making. 2010 ; 30: 341-54
11. Pinedo Villanueva RA, Turner D, Judge A, et al. Mapping the Oxford hip score onto the EQ-5D utility index. Qual Life Res. 2013 ; 22 (3). 665-75
12. Maddala GS Cambridge, UK: Cambridge University Press ; 1983 :
13. BoesS. REGOPROB: Stata module to estimate random effects generalized ordered probit models. Statistical Software Components S456604, Boston College Department of Economics, revised 6 September 2006. Available at: URL: http://ideas.repec.org/c/boc/bocode/s456604.html#biblio
14. Corana A, Marchesi C, Martini C, Ridella S. Minimizing multimodal functions of continuous variables with the "simulated annealing" algorithm. ACM Trans Math Softw. 1987 ; 13: 262-80
15. Goffe NL, Ferrier GD, Rogers J. Global optimization of statistical functions with simulated annealing. J Econom. 1994 ; 60: 65-99
16. McLachlan GJ, Peel D New York: Wiley ; 2000 :
17. Muthén B, Muthén L Users Guide.. Los Angeles, CA: Muthén and Muthén; ; 2008 :
18. Wailoo AJ, Bansback N, Brennan A, et al. Biologic drugs for rheumatoid arthritis in the medicare program: a cost effectiveness analysis. Arthritis Rheumatism. 2008 ; 58: 939-46
19. Tosh J, Brennan A, Wailoo A, Bansback N. The Sheffield rheumatoid arthritis health economic model. Rheumatology. 2011 ; 50: iv26 - iv31
20. Chen Y-F, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006 ; 10: 42
21. Wolfe F, Michaud K. The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology. 2011 ; 50: 16-24
22. SharmaTToshJLongwothLWailooAAkhurstR. Use of rituximab in patients with rheumatoid arthritis with concomitant DMARDs, or as monotherapy, for patients who are intolerant to methotrexate. Yorkshire and Humber Specialised Commissioning Group, iEDM report 5/09. Available at: URL: http://www.sheffield.nhs.uk/services/resources/rituximabforra.pdf